Reference SummaryChan PC, Toxicol Lett 2003 Oct 15;144(3):295-311

Title	Toxicity and carcinogenicity of riddelliine in rats and mice.
Authors	Chan PC; Haseman JK; Prejean JD; Nyska A
Journal	Toxicol Lett
Volume	144
Issue	3
Year	2003
Pages	295-311
Abstract	These investigations of riddelliine analyzed potential carcinogenesis and the utility of the female-rat/male-mouse design in bioassays and dose-response. Groups of 50 Fischer rats and B6C3F1 mice were gavage-administered riddelliine 5 days per week for 105 weeks. The dose levels for male rats were 0 or 1.0 mg/kg body weight; female rats 0, 0.01, 0.033, 0.1, 0.33, or 1.0 mg/kg; male mice 0, 0.1, 0.3, or 1.0, 3.0 mg/kg; and female mice 0 or 3.0 mg/kg. The dose groups were purposely designed to evaluate the dose-response relationship only in female rats and male mice. In rats, liver hemangiosarcoma, hepatocellular adenoma, and mononuclear cell leukemia were significantly increased in the 1.0 mg/kg male and female dose groups. Non-neoplastic lesions occurred in the liver and kidney of male and female rats. In mice, hemangiosarcomas increased significantly in the liver of males in the 3.0 mg/kg dose group. Alveolar/bronchiolar neoplasms in the 3.0 mg/kg dose group of female mice were significantly increased. Hepatocellular neoplasms were significantly decreased in the 1.0 mg/kg dose group of male and 3.0 mg/kg dose groups of male and female mice. Non-neoplastic lesions occurred in the liver and kidney of male and female, and lung and arteries of female mice. These studies demonstrate toxicity and carcinogenicity of riddelliine in rats and mice, and a dose-response relationship in female rats and male mice under the experimental conditions employed.
Links	J:85689 – MGI References 12927348 – National Library of Medicine/PubMed

Models
Strain	Model Name	Treatment Agent(s)	Organ Affected	Frequency	Model Details
(C57BL/6 x C3H)F1	Blood vessel hemangiosarcoma		Liver	0 - 4
(C57BL/6 x C3H)F1	Blood vessel hemangiosarcoma	riddelliine	Liver	0 - 62
(C57BL/6 x C3H)F1	Liver - Bile duct cholangioma		Liver - Bile duct	0
(C57BL/6 x C3H)F1	Liver - Bile duct cholangioma	riddelliine	Liver - Bile duct	2
(C57BL/6 x C3H)F1	Liver - Bile duct hyperplasia		Liver - Bile duct	0 - 4
(C57BL/6 x C3H)F1	Liver - Bile duct hyperplasia	riddelliine	Liver - Bile duct	0 - 56
(C57BL/6 x C3H)F1	Liver hepatocellular tumor		Liver	32.65 - 72
(C57BL/6 x C3H)F1	Liver hepatocellular tumor	riddelliine	Liver	0 - 78
(C57BL/6 x C3H)F1	Lung adenoma	riddelliine	Lung	18 - 34
(C57BL/6 x C3H)F1	Lung adenoma		Lung	2
(C57BL/6 x C3H)F1	Lung carcinoma		Lung	2
(C57BL/6 x C3H)F1	Lung carcinoma	riddelliine	Lung	8
(C57BL/6 x C3H)F1	Lung tumor		Lung	4 - 36
(C57BL/6 x C3H)F1	Lung tumor	riddelliine	Lung	26